MedTrace Logo

Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy

NCT00258180 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2019-04-16

Study results available
· View outcomes & findings →

Summary

RATIONALE: Cyclophosphamide may help control the symptoms of autoimmune enteropathy .

PURPOSE: This phase II trial is studying how well cyclophosphamide works in treating young patients with severe autoimmune enteropathy.

Conditions

  • Diarrhea
  • Gastrointestinal Complications
  • Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

BIOLOGICAL

filgrastim

Administered IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover

DRUG

cyclophosphamide

Administered IV over 1 hour on days 1-4

Sponsors & Collaborators

Principal Investigators

  • David M. Loeb, MD, PhD · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

  • Maria Oliva-Hemker, MD · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-15
Primary Completion
2009-02-24
Completion
2009-02-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00258180 on ClinicalTrials.gov